Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
Evaluate published an article under the heading "Sabinsa Takes Legal Action Against Curcumin Adulteration" dated 1 June 2015 on its website www.evaluategroup.com.
The article was subsequently removed on the direction of the Bangalore Court in case number: O.S. No.4898/2015. This article alleged that Bayir Extracts Private Limited had been referred to the police by the Magistrate Court in Bangalore and would be investigated for adulterating its curcumin products with synthetic material. In fact we have since been informed by Bayir Extracts that it had not been referred to the police, and there had been no order for an investigation into its products by that date.
We wish to apologise to Bayir Extracts for the publication of this inaccurate information, which was part of an automated citation of publicly available information at that time.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries.
Our EvaluatePharma® online subscription services provides a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.